Sandu Pharma.

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE751D01014
NSEID:
BSEID: 524703

INR

40.00

-0.2 (-0.5%)

BSENSE

Dec 05

BSE+NSE Vol: 5

{
  "main_header": {
    "sid": 764862,
    "name": "Sandu Pharma.",
    "stock_name": "Sandu Pharma.",
    "full_name": "Sandu Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/sandu-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "40.00",
    "chg": -0.2,
    "chgp": "-0.5%",
    "dir": -1,
    "prev_price": "40.20",
    "mcapval": "39.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524703,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 49,
    "indexname": "",
    "isin": "INE751D01014",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "5 ",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/sandu-pharma-764862-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Sandu Pharma. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-sandu-pharma-fallingrising-3747239",
        "imagepath": "",
        "date": "2025-12-05 00:53:47",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Context</strong></p>\n<p>Sandu Pharmaceuticals recorded a gain of ₹0.89 per share on 04-Dec, marking a 2.25% increase. This rise follows two consecutive days of gains, during which the stock has appreciated by 2.28%. Notably, the stock outperformed its sector by 2.23% on the day, signalling a positive shift in investor sentiment within its industry segment. However, the stock’s current price remains below its 20-day, 50-day, 100-day, and 200-day moving averages, although it is trading above the 5-day moving average. This technical positioning suggests that while short-term momentum is improving, the stock has yet to regain strength over longer time horizons.</p>\n<p><strong>Comparative Returns Against Benchmarks</strong></p>\n<p>Examining Sandu Pharmaceuticals’ ..."
      },
      {
        "title": "Sandu Pharmaceuticals Falls to 52-Week Low of Rs.37.01 Amidst Market Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-stock-falls-to-52-week-low-of-rs3701-3735027",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SanduPharmaceut_priceRelatedfactors_3735027.png",
        "date": "2025-11-28 09:48:44",
        "description": "Sandu Pharmaceuticals has reached a new 52-week low of Rs.37.01 today, marking a significant decline in its stock price amid broader market activity. The stock’s performance contrasts with the overall positive trend in the Sensex, highlighting ongoing challenges within the company’s financial and operational metrics."
      },
      {
        "title": "Sandu Pharmaceuticals Falls to 52-Week Low of Rs.37.01 Amidst Continued Underperformance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-stock-falls-to-52-week-low-of-rs3701-3735029",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SanduPharmaceut_priceRelatedfactors_3735029.png",
        "date": "2025-11-28 09:48:30",
        "description": "Sandu Pharmaceuticals has reached a new 52-week low of Rs.37.01 today, marking a significant decline in its stock price amid ongoing challenges in its financial performance and market positioning within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Sandu Pharmaceuticals Falls to 52-Week Low of Rs.37.21 Amid Continued Downtrend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-stock-hits-52-week-low-amidst-continued-downtrend-3729278",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SanduPharmaceut_priceRelatedfactors_3729278.png",
        "date": "2025-11-25 15:42:29",
        "description": "Sandu Pharmaceuticals touched a fresh 52-week low of Rs.37.21 today, marking a significant decline amid a sustained downward trend. The stock has recorded losses over the past three consecutive sessions, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Sandu Pharmaceuticals Falls to 52-Week Low of Rs.37.21 Amid Market Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-stock-falls-to-52-week-low-of-rs3721-3729276",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SanduPharmaceut_priceRelatedfactors_3729276.png",
        "date": "2025-11-25 15:42:28",
        "description": "Sandu Pharmaceuticals has reached a new 52-week low of Rs.37.21 today, marking a significant decline amid broader market fluctuations and sector underperformance. The stock has experienced a notable downward trend over the past three days, reflecting ongoing challenges within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Is Sandu Pharma. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-sandu-pharma-overvalued-or-undervalued-3716743",
        "imagepath": "",
        "date": "2025-11-20 08:06:19",
        "description": "As of 19 November 2025, Sandu Pharma's valuation grade has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE Ratio of 25.21, an EV to EBITDA of 13.51, and a Price to Book Value of 0.94, which suggest that the stock is trading at a reasonable price relative to its earnings and book value.\n\nIn comparison to its peers, Sandu Pharma's valuation appears favorable. For instance, Elitecon International is categorized as very expensive with a PE Ratio of 265.8, while PTC India, deemed very attractive, has a significantly lower PE Ratio of 7.5. Despite recent underperformance, with a year-to-date return of -28.92% compared to the Sensex's 9.02%, the attractive valuation grade and competitive ratios position Sandu Pharma as a potential buying opportunity in the pharmaceuticals and b..."
      },
      {
        "title": "Why is Sandu Pharma. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-sandu-pharma-fallingrising-3712899",
        "imagepath": "",
        "date": "2025-11-18 22:04:02",
        "description": "As of 18-Nov, Sandu Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at Rs. 41.78, which represents a decrease of Rs. 1.05 or 2.45%. The stock has hit a new 52-week low of Rs. 38 today, reflecting a significant drop of 11.28% at its intraday low. Over the past week, the stock has underperformed its sector by 1.89% and has seen a consecutive fall over the last two days, accumulating a total decline of 3.98%. Additionally, the stock is trading below its moving averages across various time frames, indicating a bearish trend. There has also been a notable decrease in investor participation, with delivery volume dropping by 71.14% compared to the five-day average, which further suggests weakening investor interest.\n\nIn the broader market context, Sandu Pharmaceuticals has underperformed significantly compared to the Sensex, with a year-to-date return of -27.03% against the benchmark's ..."
      },
      {
        "title": "Sandu Pharmaceuticals Falls to 52-Week Low of Rs.38 Amidst Continued Downtrend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-falls-to-52-week-low-of-rs38-on-18-nov-2025-3711956",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SanduPharmaceut_priceRelatedfactors_3711956.png",
        "date": "2025-11-18 13:28:25",
        "description": "Sandu Pharmaceuticals has reached a new 52-week low of Rs.38, marking a significant decline in its stock price amid ongoing downward momentum. The stock has underperformed its sector and benchmark indices, reflecting persistent challenges in its financial performance and market positioning."
      },
      {
        "title": "Sandu Pharmaceuticals Stock Plummets to New 52-Week Low at Rs. 40.21",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-stock-plummets-to-new-52-week-low-at-rs-4021-3707267",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SanduPharmaceut_priceRelatedfactors_3707267.png",
        "date": "2025-11-17 11:09:47",
        "description": "Sandu Pharmaceuticals has hit a new 52-week low, reflecting a significant decline in its stock performance. The company has underperformed its sector and experienced a notable drop over the past year. Financial metrics indicate challenges, including low Return on Equity and concerns regarding debt management."
      }
    ],
    "total": 78,
    "sid": "764862",
    "stock_news_url": "https://www.marketsmojo.com/news/sandu-pharmaceuticals-764862"
  },
  "announcements": [
    {
      "caption": "Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot",
      "datetime": "19-Nov-2025",
      "details": "Outcome of the Postal Ballot pertaining to reclassification of M/s Akshath Finvest and Properties Private Limited from Promoter Group category to Public category",
      "source": "BSE"
    },
    {
      "caption": ": Intimation Regarding Receipt Of Approval Of Shareholders For Reclassification Of M/S Akshath Finvest And Properties Private Limited Persons Forming Part Of The Promoter/Promoter Group Category To The Public Category.",
      "datetime": "19-Nov-2025",
      "details": "Postal Ballot approval on reclassification of Promoter into Public",
      "source": "BSE"
    },
    {
      "caption": "Shareholder Meeting / Postal Ballot-Scrutinizers Report",
      "datetime": "19-Nov-2025",
      "details": "Scrutinizers report inrespect of Postal ballot for reclassification of M/s Akshath Finvest and Properties Private Limited from Promoter Group Category to Public Category",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Sandu Pharmaceuticals Ltd has declared <strong>8%</strong> dividend, ex-date: 18 Sep 25",
          "dt": "2025-09-18",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Why is Sandu Pharma. falling/rising?

2025-12-05 00:53:47

Recent Price Movement and Market Context

Sandu Pharmaceuticals recorded a gain of ₹0.89 per share on 04-Dec, marking a 2.25% increase. This rise follows two consecutive days of gains, during which the stock has appreciated by 2.28%. Notably, the stock outperformed its sector by 2.23% on the day, signalling a positive shift in investor sentiment within its industry segment. However, the stock’s current price remains below its 20-day, 50-day, 100-day, and 200-day moving averages, although it is trading above the 5-day moving average. This technical positioning suggests that while short-term momentum is improving, the stock has yet to regain strength over longer time horizons.

Comparative Returns Against Benchmarks

Examining Sandu Pharmaceuticals’ ...

Sandu Pharmaceuticals Falls to 52-Week Low of Rs.37.01 Amidst Market Pressure

2025-11-28 09:48:44

Sandu Pharmaceuticals has reached a new 52-week low of Rs.37.01 today, marking a significant decline in its stock price amid broader market activity. The stock’s performance contrasts with the overall positive trend in the Sensex, highlighting ongoing challenges within the company’s financial and operational metrics.

Sandu Pharmaceuticals Falls to 52-Week Low of Rs.37.01 Amidst Continued Underperformance

2025-11-28 09:48:30

Sandu Pharmaceuticals has reached a new 52-week low of Rs.37.01 today, marking a significant decline in its stock price amid ongoing challenges in its financial performance and market positioning within the Pharmaceuticals & Biotechnology sector.

Sandu Pharmaceuticals Falls to 52-Week Low of Rs.37.21 Amid Continued Downtrend

2025-11-25 15:42:29

Sandu Pharmaceuticals touched a fresh 52-week low of Rs.37.21 today, marking a significant decline amid a sustained downward trend. The stock has recorded losses over the past three consecutive sessions, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.

Sandu Pharmaceuticals Falls to 52-Week Low of Rs.37.21 Amid Market Pressure

2025-11-25 15:42:28

Sandu Pharmaceuticals has reached a new 52-week low of Rs.37.21 today, marking a significant decline amid broader market fluctuations and sector underperformance. The stock has experienced a notable downward trend over the past three days, reflecting ongoing challenges within the Pharmaceuticals & Biotechnology sector.

Is Sandu Pharma. overvalued or undervalued?

2025-11-20 08:06:19

As of 19 November 2025, Sandu Pharma's valuation grade has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE Ratio of 25.21, an EV to EBITDA of 13.51, and a Price to Book Value of 0.94, which suggest that the stock is trading at a reasonable price relative to its earnings and book value. In comparison to its peers, Sandu Pharma's valuation appears favorable. For instance, Elitecon International is categorized as very expensive with a PE Ratio of 265.8, while PTC India, deemed very attractive, has a significantly lower PE Ratio of 7.5. Despite recent underperformance, with a year-to-date return of -28.92% compared to the Sensex's 9.02%, the attractive valuation grade and competitive ratios position Sandu Pharma as a potential buying opportunity in the pharmaceuticals and b...

Why is Sandu Pharma. falling/rising?

2025-11-18 22:04:02

As of 18-Nov, Sandu Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at Rs. 41.78, which represents a decrease of Rs. 1.05 or 2.45%. The stock has hit a new 52-week low of Rs. 38 today, reflecting a significant drop of 11.28% at its intraday low. Over the past week, the stock has underperformed its sector by 1.89% and has seen a consecutive fall over the last two days, accumulating a total decline of 3.98%. Additionally, the stock is trading below its moving averages across various time frames, indicating a bearish trend. There has also been a notable decrease in investor participation, with delivery volume dropping by 71.14% compared to the five-day average, which further suggests weakening investor interest. In the broader market context, Sandu Pharmaceuticals has underperformed significantly compared to the Sensex, with a year-to-date return of -27.03% against the benchmark's ...

Sandu Pharmaceuticals Falls to 52-Week Low of Rs.38 Amidst Continued Downtrend

2025-11-18 13:28:25

Sandu Pharmaceuticals has reached a new 52-week low of Rs.38, marking a significant decline in its stock price amid ongoing downward momentum. The stock has underperformed its sector and benchmark indices, reflecting persistent challenges in its financial performance and market positioning.

Sandu Pharmaceuticals Stock Plummets to New 52-Week Low at Rs. 40.21

2025-11-17 11:09:47

Sandu Pharmaceuticals has hit a new 52-week low, reflecting a significant decline in its stock performance. The company has underperformed its sector and experienced a notable drop over the past year. Financial metrics indicate challenges, including low Return on Equity and concerns regarding debt management.

View All News

Announcement

Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot

19-Nov-2025 | Source : BSE

Outcome of the Postal Ballot pertaining to reclassification of M/s Akshath Finvest and Properties Private Limited from Promoter Group category to Public category

: Intimation Regarding Receipt Of Approval Of Shareholders For Reclassification Of M/S Akshath Finvest And Properties Private Limited Persons Forming Part Of The Promoter/Promoter Group Category To The Public Category.

19-Nov-2025 | Source : BSE

Postal Ballot approval on reclassification of Promoter into Public

Shareholder Meeting / Postal Ballot-Scrutinizers Report

19-Nov-2025 | Source : BSE

Scrutinizers report inrespect of Postal ballot for reclassification of M/s Akshath Finvest and Properties Private Limited from Promoter Group Category to Public Category